Dinçer Burak, Gök Ali Fuat Kaan, İlhan Mehmet, Ercan Leman Damla, Kulle Cemil Burak, Ercan Celal Caner, Berker Neslihan, Ertekin Cemalettin
Department of Surgical Oncology, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Türkiye.
Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Türkiye.
BMC Cancer. 2025 Mar 15;25(1):479. doi: 10.1186/s12885-025-13858-x.
Cytoreductive Surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are techniques developed for curative treatment of peritoneal carcinomatosis (PC). Studies have shown that CRS + HIPEC provides a survival advantage in PC, and long-term survival can be achieved in selected cases. This study aimed to evaluate CRS + HIPEC cases performed for curative purposes and to examine the prognostic factors.
PC patients who underwent CRS + HIPEC with curative intent between January 2011 and September 2022 were included. Demographic, clinical, and pathological findings, procedure-specific parameters, complications, mortality, progression-free survival (PFS), and overall survival (OS) were analyzed.
Optimal cytoreduction was achieved in 70% of the patients. The median PFS for the entire series was 9.2 months, while the median OS was 20.5 months, with a 3-year OS rate of 36%. Appendiceal origin, cytoreduction score, absence of lymph node metastasis, and absence of complications were factors associated with a positive impact on both PFS and OS. In multivariate analysis, cytoreduction score emerged as the sole independent factor influencing both PFS and OS.
Considering the results in our series, cases of PC in which complete cytoreduction can be achieved should be evaluated for CRS + HIPEC.
细胞减灭术（CRS）和腹腔内热灌注化疗（HIPEC）是为腹膜癌病（PC）的根治性治疗而开发的技术。研究表明，CRS+HIPEC在PC治疗中具有生存优势，部分病例可实现长期生存。本研究旨在评估以根治为目的进行的CRS+HIPEC病例，并探讨预后因素。
纳入2011年1月至2022年9月间接受根治性CRS+HIPEC的PC患者。分析患者的人口统计学、临床和病理特征、手术相关参数、并发症、死亡率、无进展生存期（PFS）和总生存期（OS）。
70%的患者实现了最佳细胞减灭。整个队列的中位PFS为9.2个月，中位OS为20.5个月，3年OS率为36%。阑尾起源、细胞减灭评分、无淋巴结转移和无并发症是对PFS和OS均有积极影响的因素。多因素分析显示，细胞减灭评分是影响PFS和OS的唯一独立因素。
根据我们队列的结果，对于能够实现完全细胞减灭的PC病例，应评估其是否适合进行CRS+HIPEC。
